BioLite, Inc. formed an alliance with American BriVision Corporation (ABVC) to co-develop the US market for its new drugs
including combination therapy for Triple-negative breast cancer (TNBC), cancer combination therapy,
Hematology-Chronic Lymphocytic Leukemia (HCLL), Attention Deficit Hyperactivity Disorder(ADHD) and Major Depressive Disorder.
For the cancer combination therapy project, BioLite, Inc. has initiated the co-operation with an oversea partner, and is also technically
supported by a US renowned cancer center. These partners also came to support the BioLite-sponsored
International Symposium on Hematology & Oncology held in Oct., 2015, Taipei.
3F., No. 18, Ln. 321, Yangguang St., Neihu Dist., Taipei City 114067, Taiwan (R.O.C.) TEL:+886 2 8751-8701 FAX:+886 2 8751-8605 Copyright ©2015 BioLite, Inc. All Rights Reserved. |